Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Purpose: The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Results: The mouthwash had a satisfactory shelf life and was well ...

Lipella Pharmaceuticals has concluded subject enrollment in its multicentre Phase IIa trial of liposomal tacrolimus oral rinse LP-310, which is aimed at treating oral lichen planus (OLP). The ...

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating ...

Lipella Pharmaceuticals Inc. announced that its abstract on LP-10, a liposomal tacrolimus oral rinse for treating Oral Lichen Planus (OLP), will be presented by Dr. Alessandro Villa at the 2025 ...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” ...

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...

The post Lipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen Planus appeared first on PRISM MarketView.

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...